Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy  

作　　者：Michail Galanopoulos Aris Doukatas Filippos Gkeros Nikos Viazis Christos Liatsos 

机构地区：[1]Department of Gastroenterology,Addenbrooke’s Hospital,Cambridge CB20QQ,United Kingdom [2]Department of Pharmacy,National and Kapodistrian University of Athens,Athens GR 15772,Greece [3]Department of Gastroenterology,Evangelismos,Ophthalmiatreion Athinon and Polyclinic Hospitals,Athens 10676,Greece [4]Department of Gastroenterology,401 General Military Hospital,Athens 11525,Greece

出　　处：《World Journal of Gastroenterology》2021年第24期3568-3580,共13页世界胃肠病学杂志（英文版）

摘　　要：Pancreatic cancer is one of the highest and in fact,unchanged mortality-associated tumor,with an exceptionally low survival rate due to its challenging diagnostic approach.So far,its treatment is based on a combination of approaches(such as surgical resection with or rarely without chemotherapeutic agents),but with finite limits.Thus,looking for additional space to improve pancreatic tumorigenesis therapeutic approach,research has focused on gene therapy with unexpectedly growing horizons not only for the treatment of inoperable pancreatic disease,but also for its early stages.In vivo gene delivery viral vectors,despite few disadvantages(possible immunogenicity,toxicity,mutagenicity,or high cost),could be one of the most efficient cancer gene therapeutic strategies for clinical application due to their superiority compared with other systems(ex vivo delivery strategies).Their dominance consists of simple preparation,easy operation and a wide range of functions.Adenoviruses are one of the most common used vectors,inducing strong immune as well as inflammatory reactions.Oncolytic virotherapy,using the above mentioned in vivo viral vectors,is one of the most promising nonpathogenic,highly-selective cytotoxic anti-cancer therapy using anti-cancer agents with high anti-tumor potency and strong oncolytic effect.There have been a variety of targeted therapeutic and pre-clinical strategies tested for gene therapy in pancreatic cancer such as gene-editing systems(e.g.,clustered regularly interspaced palindromic repeats-Cas9),RNA interference technology(e.g.,microRNAs,short hairpin RNA or small interfering RNA),adoptive immunotherapy and vaccination(e.g.,chimeric antigen receptor T-cell therapy)with encouraging results.

关 键 词：Pancreatic cancer Gene therapy Viral vectors Gene editing miRNA SIRNA Oncolytic virotherapy 

分 类 号：R735.9[医药卫生—肿瘤]